Prostate cancer: Clinical practice guidelines in oncology™

James Mohler; Robert R. Bahnson; Barry Boston; J. Erik Busby; Anthony D'Amico; James A. Eastham; Charles A. Enke; Daniel George; Eric Mark Horwitz; Robert P. Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H. Lange; Gary MacVicar; Elizabeth R. Plimack; Julio M. Pow-Sang; Mack Roach; Eric Rohren; Bruce J. Roth; Dennis C. Shrieve; Matthew R. Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C. Walsh

doi:10.6004/jnccn.2010.0012

Prostate cancer: Clinical practice guidelines in oncology™

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach, Eric Rohren, Bruce J. RothDennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, Patrick C. Walsh

Nuclear Medicine

Research output: Contribution to journal › Review article › peer-review

613 Scopus citations

Abstract

The intention of these guidelines is to provide a framework on which to base treatment decisions. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support treatment recommendations. Several variables (including life expectancy, disease characteristics, predicted outcomes, and patient preferences) must be considered by patients and physicians when tailoring prostate cancer therapy to the individual patient.

Original language	English (US)
Pages (from-to)	162-200
Number of pages	39
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	8
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2010.0012
State	Published - Feb 2010

Keywords

Active surveillance
Early detection
Life expectancy estimation
NCCN clinical practice guidelines
Prostate cancer
Prostate-specific antigen
Radiation therapy
Radical prostatectomy
Screening

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2010.0012

Cite this

Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., Kantoff, P., Kawachi, M., Kuettel, M., Lange, P. H., MacVicar, G., Plimack, E. R., Pow-Sang, J. M., Roach, M., Rohren, E., ... Walsh, P. C. (2010). Prostate cancer: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 8(2), 162-200. https://doi.org/10.6004/jnccn.2010.0012

Mohler, J, Bahnson, RR, Boston, B, Busby, JE, D'Amico, A, Eastham, JA, Enke, CA, George, D, Horwitz, EM, Huben, RP, Kantoff, P, Kawachi, M, Kuettel, M, Lange, PH, MacVicar, G, Plimack, ER, Pow-Sang, JM, Roach, M, Rohren, E, Roth, BJ, Shrieve, DC, Smith, MR, Srinivas, S, Twardowski, P & Walsh, PC 2010, 'Prostate cancer: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 2, pp. 162-200. https://doi.org/10.6004/jnccn.2010.0012

@article{9a97c5bea7b44c6e99be227ef9897752,

title = "Prostate cancer: Clinical practice guidelines in oncology{\texttrademark}",

abstract = "The intention of these guidelines is to provide a framework on which to base treatment decisions. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support treatment recommendations. Several variables (including life expectancy, disease characteristics, predicted outcomes, and patient preferences) must be considered by patients and physicians when tailoring prostate cancer therapy to the individual patient.",

keywords = "Active surveillance, Early detection, Life expectancy estimation, NCCN clinical practice guidelines, Prostate cancer, Prostate-specific antigen, Radiation therapy, Radical prostatectomy, Screening",

author = "James Mohler and Bahnson, {Robert R.} and Barry Boston and Busby, {J. Erik} and Anthony D'Amico and Eastham, {James A.} and Enke, {Charles A.} and Daniel George and Horwitz, {Eric Mark} and Huben, {Robert P.} and Philip Kantoff and Mark Kawachi and Michael Kuettel and Lange, {Paul H.} and Gary MacVicar and Plimack, {Elizabeth R.} and Pow-Sang, {Julio M.} and Mack Roach and Eric Rohren and Roth, {Bruce J.} and Shrieve, {Dennis C.} and Smith, {Matthew R.} and Sandy Srinivas and Przemyslaw Twardowski and Walsh, {Patrick C.}",

year = "2010",

month = feb,

doi = "10.6004/jnccn.2010.0012",

language = "English (US)",

volume = "8",

pages = "162--200",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Prostate cancer

T2 - Clinical practice guidelines in oncology™

AU - Mohler, James

AU - Bahnson, Robert R.

AU - Boston, Barry

AU - Busby, J. Erik

AU - D'Amico, Anthony

AU - Eastham, James A.

AU - Enke, Charles A.

AU - George, Daniel

AU - Horwitz, Eric Mark

AU - Huben, Robert P.

AU - Kantoff, Philip

AU - Kawachi, Mark

AU - Kuettel, Michael

AU - Lange, Paul H.

AU - MacVicar, Gary

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Roach, Mack

AU - Rohren, Eric

AU - Roth, Bruce J.

AU - Shrieve, Dennis C.

AU - Smith, Matthew R.

AU - Srinivas, Sandy

AU - Twardowski, Przemyslaw

AU - Walsh, Patrick C.

PY - 2010/2

Y1 - 2010/2

N2 - The intention of these guidelines is to provide a framework on which to base treatment decisions. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support treatment recommendations. Several variables (including life expectancy, disease characteristics, predicted outcomes, and patient preferences) must be considered by patients and physicians when tailoring prostate cancer therapy to the individual patient.

AB - The intention of these guidelines is to provide a framework on which to base treatment decisions. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support treatment recommendations. Several variables (including life expectancy, disease characteristics, predicted outcomes, and patient preferences) must be considered by patients and physicians when tailoring prostate cancer therapy to the individual patient.

KW - Active surveillance

KW - Early detection

KW - Life expectancy estimation

KW - NCCN clinical practice guidelines

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Radiation therapy

KW - Radical prostatectomy

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77649158894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649158894&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2010.0012

DO - 10.6004/jnccn.2010.0012

M3 - Review article

C2 - 20141676

AN - SCOPUS:77649158894

SN - 1540-1405

VL - 8

SP - 162

EP - 200

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Prostate cancer: Clinical practice guidelines in oncology™

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this